2316. Serostatus Following Polio-containing Vaccination Before and After Liver Transplantation 
Session: Poster Abstract Session: Transplants: Infection Epidemiology and Outcome in Solid Organ Transplantation
Saturday, October 29, 2016
Room: Poster Hall
  • 20161021_Funaki, IDweek2016 poster_2016.10.29 .pdf (170.8 kB)
  • Background: Polio is one of the most catastrophic infectious diseases in the world. Therefore, the strategy to eradicate polio is based on preventing infection by immunizing all children until the world is polio-free. However, data regarding effectiveness of polio-containing vaccination in immunocompromised patients, especially in those who received liver transplantation (LT) is limited.

    Methods: We conducted an observational study at the largest pediatric transplant center in Japan from January 2011 to January 2015. Patients who required LT and completed the Japanese polio vaccination program (oral polio vaccine (OPV) twice, or OPV once and three doses of the polio-containing inactivated vaccines, or four doses of the polio-containing inactivated vaccines) were enrolled. Patients’ demographics were collected from their medical records. Antibody titers against poliovirus serotypes 1-3 were measured using the neutralization test at various times after enrollment.

    Results: Sixty eight patients had received the complete polio vaccination series and were enrolled. Of these, 38 patients had received all vaccines before LT. Median age of the patients was 69 months (IQR: 47-94), and 45 (66%) were female. Their underlying diseases included; 43 (63%) with cholestatic liver diseases, 12 (18%) with metabolic disorders, and fulminant 6 (9%) with hepatic failure. The seropositivity rates were 100% (polio 1), 100% (polio 2), and 78.9% (polio 3), in 19 patients prior to LT. After a median interval of 11 months (IQR 8-28) after LT, seropositivity rates against poliovirus 1, 2, and 3 were 94.1% (64/68), 91.2% (62/68), and 54.4% (37/68), respectively.

    Conclusion: In the LT recipients, antibody titers against poliovirus appeared to wane within a relatively short period of time. Seropositivity against poliovirus 3 was particularly low compared to other serotypes after LT. Additional inactivated polio-containing vaccination may be needed after LT.

    Takanori Funaki, MD1, Akinari Fukuda, MD, PhD2, Seisuke Sakamoto, MD, PhD2, Mureo Kasahara, MD, PhD2, Akihiko Saitoh, MD, PhD1,3 and Isao Miyairi, MD1,4, (1)Infectious Disease, National Center for Child Health and Development, Tokyo, Japan, (2)Transplantation Center, National Center for Child Health and Development, Tokyo, Japan, (3)Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, (4)St Jude Children's Research Hospital, Memphis, TN


    T. Funaki, None

    A. Fukuda, None

    S. Sakamoto, None

    M. Kasahara, None

    A. Saitoh, None

    I. Miyairi, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.